Clover Health Investments, Corp.
NASDAQ:CLOV · NASDAQ Global Select
+$0.17 today
Vol 7.06M · Avg 7.31M
Cash Flow
Check whether earnings turn into cash
Use operating cash flow, capital spending, free cash flow, and financing activity to see how much value is left for reinvestment or owners.
Free Cash Flow
Net Income to FCF bridge
Analysis
Analysis will appear once cash flow data is available for this period.
Cash Flow Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Net Income | -$85.5M -98.9% | -$43.0M +79.8% | -$213.4M +37.2% | -$339.6M +42.2% | -$587.8M | $487.6M | $476.4M | $465.2M |
| Depreciation & Amortization | $1.7M +26.7% | $1.3M -47.0% | $2.5M +111.4% | $1.2M -4.7% | $1.2M | $374.2M | $1.2B | $631.8M |
| Deferred Income Tax | $0 | $0 | $0 | $0 +100.0% | -$66.1M | $1.4B | -$1.5B | $304.2M |
| Stock-Based Compensation | $103.7M -9.3% | $114.3M -18.9% | $140.9M -14.2% | $164.3M +0.4% | $163.7M | $489.0M | $354.6M | -$1.6B |
| Change in Working Capital | -$84.2M -755.0% | $12.9M +123.2% | -$55.4M -2249.9% | -$2.4M -101.2% | $192.7M | $350.4M | -$1.6B | $1.5B |
| Accounts Receivables | -$65.9M -906.5% | -$6.6M | $0 +100.0% | -$8.0M +14.5% | -$9.4M | $592.6M | $1.3B | $626.2M |
| Inventory | $0 | $0 | $0 | $0 -100.0% | $9.4M | $1.0B | $1.2B | $1.1B |
| Accounts Payables | $1.6M +162.9% | -$2.6M -155.3% | $4.7M -37.9% | $7.6M +43.9% | $5.3M | $948.2M | -$1.5B | $433.0M |
| Other Working Capital | -$19.9M -190.3% | $22.0M +136.6% | -$60.2M -2962.2% | -$2.0M -101.0% | $187.4M | $567.4M | $1.3B | $601.0M |
| Other Non-Cash Items | -$2.5M +95.0% | -$50.7M -634.2% | $9.5M +134.5% | -$27.5M -298.1% | $13.9M | $1.4B | -$1.5B | $300.0M |
| Operating Cash Flow | -$66.9M -292.1% | $34.8M +130.1% | -$115.9M +43.2% | -$203.9M +27.8% | -$282.3M | $7.2B | $8.9B | $10.5B |
| Capital Expenditures | -$2.0M -31.3% | -$1.6M -166.4% | -$584.0K +86.9% | -$4.5M -517.8% | -$723.0K | $664.0M | $1.4B | $697.6M |
| Acquisitions (Net) | $0 | $0 | $0 +100.0% | -$16.2M -103.7% | $434.7M | $937.0M | $1.1B | $1.3B |
| Purchases of Investments | -$205.1M -1.9% | -$201.2M -14.6% | -$175.6M +52.5% | -$369.6M +57.8% | -$876.3M | $444.2M | $1.4B | $1.3B |
| Sales of Investments | $211.2M +3.9% | $203.4M -35.7% | $316.2M -34.9% | $485.4M +9.9% | $441.5M | $822.2M | $318.2M | -$1.5B |
| Other Investing Activities | $0 | $0 | $0 | $0 +100.0% | -$434.7M | $616.4M | $370.0M | $1.2B |
| Investing Cash Flow | $4.1M +621.4% | $565.0K -99.6% | $140.0M +47.2% | $95.1M +121.8% | -$435.4M | $4.8B | $6.4B | $5.1B |
| Debt Repayment | $0 | $0 | $0 | $0 +100.0% | -$30.9M | $680.8M | $759.2M | $1.1B |
| Common Stock Issued | $1.8M +101.1% | $902.0K -21.6% | $1.1M -17.9% | $1.4M -99.5% | $289.9M | $778.8M | $946.8M | $812.4M |
| Common Stock Repurchased | -$55.2M -202.2% | -$18.3M -193.6% | -$6.2M +2.2% | -$6.4M -4227.9% | -$147.0K | $351.8M | -$1.6B | $1.5B |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 | $535.2M | $613.6M | $692.0M |
| Other Financing Activities | $0 | $0 +100.0% | -$28.8M | $0 -100.0% | $666.5M | -$1.6B | $1.3B | $1.1B |
| Financing Cash Flow | -$53.4M -207.5% | -$17.4M +48.7% | -$33.9M -582.4% | -$5.0M -100.5% | $925.4M | $12.2B | $13.9B | -$15.5B |
| Effect of Forex Changes | $0 | $0 | $0 | $0 | $0 | $1.3B | $1.1B | $990.2M |
| Net Change in Cash | -$116.2M -744.0% | $18.0M +285.7% | -$9.7M +91.5% | -$113.8M -154.8% | $207.6M | $3.2B | $4.9B | $6.5B |
| Free Cash Flow | -$69.0M -307.2% | $33.3M +128.6% | -$116.5M +44.1% | -$208.4M +26.4% | -$283.0M | $8.6B | -$16.8B | $11.1B |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Twist Bioscience Corporation
NASDAQ:TWST
$5.34B
10x Genomics, Inc.
NASDAQ:TXG
$4.42B
LifeStance Health Group, Inc.
NASDAQ:LFST
$3.42B
National HealthCare Corporation
AMEX:NHC
$3.02B
Guardian Pharmacy Services, Inc.
NYSE:GRDN
$2.76B
Structure Therapeutics Inc.
NASDAQ:GPCR
$2.63B
PROCEPT BioRobotics Corporation
NASDAQ:PRCT
$1.22B
QuidelOrtho Corporation
NASDAQ:QDEL
$898.91M
Certara, Inc.
NASDAQ:CERT
$891.23M
BGM Group Ltd.
NASDAQ:BGM
$74.69M
SEC Filings
Recent regulatory filings
No filings found.
Does CLOV generate free cash flow?
Clover Health Investments, Corp. (CLOV) generated -$68,977,000.00 of free cash flow in fiscal 2025.
How much operating cash flow does CLOV produce?
Operating cash flow was -$66,934,000.00, before capital expenditures of $2.04M.
Explore More
Continue the stock analysis
Jump to another research area for this company.